Incyte To Seek Another Monjuvi Approval In Crowded CD19-Targeting Market

Interest Growing Across Indications

Incyte reported positive topline Phase III results for Monjuvi in relapsed or refractory follicular lymphoma and plans to file for US FDA approval by the end of 2024.

Business candle stick graph chart of stock market investment trading on blue background — Follicular lymphoma may help Monjuvi revenue grow into the hundreds of millions of dollars • Source: Shutterstock

Incyte Corporation reported positive topline results from the Phase III inMIND clinical trial of its CD19-targeting monoclonal antibody Monjuvi (tafasitamab) in relapsed or refractory follicular lymphoma (FL) on 16 August and said it will file a supplemental biologics license application (sBLA) with the US Food and Drug Administration for the indication by the end of this year. FL is one of two indications the company is targeting for near- to mid-term growth in an increasingly crowded drug class.

Key Takeaways

Incyte plans to seek US FDA approval for Monjuvi in relapsed or refractory follicular lymphoma (FL) by the end of 2024 based on positive topline results...

In February, Wilmington, DE-based Incyte agreed to pay $25m to obtain exclusive global rights to Monjuvi from its partner MorphoSys AG as Novartis AG acquired the German biotechnology...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

29 May 2025

• By Jessica Merrill

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

29 May 2025

• By Andrew McConaghie

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

29 May 2025

• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

28 May 2025

• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.